Zota Health Care

Who are in the management team of Zota Health Care?

As of March 2020, the management team of Zota Health Care includes Chairman Ketankumar Zota, Managing Director Moxesh Zota, and several Whole-time Directors, along with independent directors and a company secretary. Key members are Kamlesh Zota, Himanshu Zota, Manukant Zota, Varsaben Mehta, Ashvin Variya, Bhumi Maulik Doshi, Dhiren Prafulbhai Shah, and Jayshreeben N Mehta.

As of March 2020, the management team of Zota Health Care includes the following members:<BR><BR>1. Ketankumar Zota - Chairman & Non Executive Director<BR>2. Moxesh Zota - Managing Director<BR>3. Kamlesh Zota - Whole-time Director<BR>4. Himanshu Zota - Whole-time Director<BR>5. Manukant Zota - Whole-time Director<BR>6. Varsaben Mehta - Independent Director<BR>7. Ashvin Variya - Company Secretary<BR>8. Bhumi Maulik Doshi - Additional Independent Director<BR>9. Dhiren Prafulbhai Shah - Independent Director<BR>10. Jayshreeben N Mehta - Independent Director<BR><BR>Each member holds a specific role that contributes to the governance and management of the company.

When is the next results date for Zota Health Care?

No Upcoming Board Meetings

What is the bonus history of the Zota Health Care?

Zota Health Care announced a 4:10 bonus issue on July 25, 2019, with a record date of July 26, 2019, meaning shareholders received 4 additional shares for every 10 shares held.

Zota Health Care has a bonus history that includes a 4:10 bonus issue announced on July 25, 2019. The record date for this bonus was July 26, 2019. This means that for every 10 shares held, shareholders received an additional 4 shares as part of this bonus issue. If you have any more questions about Zota Health Care or need further details, feel free to ask!

Has Zota Health Care declared dividend?

Zota Health Care Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 20, 2024. Despite a low dividend yield of 0.1%, the company has shown strong price returns, achieving a total return of 579.53% over the past five years.

Zota Health Care Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Zota Health Care achieved a price return of 56.73% with no dividend return, resulting in a total return of 56.73%.<BR><BR>Over the past year, the company recorded a price return of 103.34% and a dividend return of 0.19%, leading to a total return of 103.53%.<BR><BR>In the two-year period, Zota Health Care experienced a price return of 205.08% and a dividend return of 0.55%, culminating in a total return of 205.63%.<BR><BR>For the three-year period, the price return was 247.63% with a dividend return of 1.44%, resulting in a total return of 249.07%.<BR><BR>Over the last four years, the company saw a price return of 450.58% and a dividend return of 2.30%, achieving a total return of 452.88%.<BR><BR>In the five-year span, Zota Health Care had a price return of 575.72% and a dividend return of 3.81%, leading to a total return of 579.53%.<BR><BR>Overall, Zota Health Care has declared a dividend, and while the dividend yield is relatively low, the company has demonstrated strong price returns across all periods, indicating robust growth and potential for investors.

Who are the peers of the Zota Health Care?

Zota Health Care's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Indoco Remedies, Senores Pharma, and SMS Pharma. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Zota Health Care's 1-year return is 0.00%, lower than its peers.

Peers: The peers of Zota Health Care are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Indoco Remedies, Senores Pharma., and SMS Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Average management risk is found at IOL Chemicals, Novartis India, Indoco Remedies, SMS Pharma., and the rest. Below Average management risk is noted for Senores Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest, while below average growth is seen in Divi's Lab., Torrent Pharma, IOL Chemicals, Indoco Remedies, SMS Pharma., and the rest. Good growth is observed at Novartis India, while Senores Pharma. shows excellent growth.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cipla has the lowest at 0.86%. Zota Health Care's 1-year return is 0.00%, which is lower than both. Additionally, IOL Chemicals, Novartis India, Indoco Remedies, and SMS Pharma. have negative six-month returns.

Is Zota Health Care overvalued or undervalued?

As of February 14, 2023, Zota Health Care is considered risky and overvalued with poor financial metrics, including a PE ratio of -49.15 and a ROE of -25.21%, despite having outperformed the Sensex with a 1-year return of 93.8%.

As of 14 February 2023, the valuation grade for Zota Health Care has moved from expensive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued, with a PE ratio of -49.15, an EV to EBITDA of -507.40, and a Price to Book Value of 12.39. These ratios suggest that the company's financial performance is not only poor but also unsustainable at its current valuation.<BR><BR>In comparison to its peers, Zota Health Care's valuation metrics are concerning, particularly when looking at the negative PEG ratio of 0.00 and a ROE of -25.21%. While some peers may have better financial health, Zota's metrics highlight its struggles in generating returns. Notably, the stock has outperformed the Sensex over various time frames, including a 1-year return of 93.8% compared to the Sensex's 7.87%, but this performance does not mitigate the underlying valuation concerns.

What does Zota Health Care do?

Zota Health Care Ltd is a pharmaceutical company that manufactures and markets pharmaceutical, ayurvedic, nutraceutical, and OTC products. As of March 2025, it reported net sales of 973 Cr and a net loss of 129 Cr, with a market cap of INR 3,556 Cr.

Overview: <BR>Zota Health Care Ltd is a pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History: <BR>Zota Health Care Limited was incorporated on July 12, 2000. The latest quarterly results reported are for March 2025, showcasing the company's current sales and profit status.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 973 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -129 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 3,556 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.08% <BR>Debt-Equity: 0.61 <BR>Return on Equity: -25.21% <BR>Price to Book: 15.70<BR><BR>Contact Details: <BR>Address: Zota House 2/896 Hira Modi St, Sagrampura Surat Gujarat : 395002 <BR>Tel: 91-261-2331601 <BR>Email: info@zotahealthcare.com <BR>Website: http://www.zotahealthcare.com

Who are the top shareholders of the Zota Health Care?

The top shareholders of Zota Health Care include Himansubhai Muktilal Zota, the largest individual shareholder with 10.65%, and Asha Mukul Agrawal, the highest public shareholder at 5.54%. Promoters hold a pledged 0.2573%, while 11 Foreign Institutional Investors own 3.6%, and individual investors collectively hold 24.79%.

The top shareholders of Zota Health Care include the promoters, with Himansubhai Muktilal Zota being the largest individual shareholder, holding 10.65% of the company. Additionally, Asha Mukul Agrawal is the highest public shareholder, owning 5.54%. The company also has 11 Foreign Institutional Investors (FIIs) holding a combined 3.6%. Individual investors collectively hold 24.79% of the shares. Notably, the promoters have a pledged holding of 0.2573%.

How big is Zota Health Care?

As of 24th July, Zota Health Care Ltd has a market capitalization of 3,483.00 Cr, with recent net sales of 292.97 Cr and a net profit loss of 56.39 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Zota Health Care Ltd has a market capitalization of 3,483.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 292.97 Cr, while the sum of Net Profit for the same period reflects a loss of 56.39 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 89.98 Cr and Total Assets valued at 223.93 Cr.

How has been the historical performance of Zota Health Care?

Zota Health Care has experienced significant revenue growth, increasing from 85.63 Cr in March 2019 to 292.97 Cr in March 2025, but has faced severe profitability declines, reporting a loss of -56.74 Cr in March 2025 compared to a profit of 8.91 Cr in March 2022, alongside deteriorating cash flow and rising debt.

Answer:<BR>The historical performance of Zota Health Care shows significant fluctuations in revenue and profitability over the years, culminating in a challenging fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Zota Health Care's net sales have shown a consistent upward trend, increasing from 85.63 Cr in March 2019 to 292.97 Cr in March 2025. However, the total expenditure has also risen sharply, reaching 298.70 Cr in March 2025, which has led to an operating profit (PBDIT) of -5.73 Cr, a stark decline from the positive figures seen in previous years. The company reported a profit before tax of -57.64 Cr in March 2025, compared to a profit of 12.44 Cr in March 2022, indicating a significant downturn. The profit after tax has similarly worsened, resulting in a loss of -56.74 Cr in March 2025, down from a profit of 8.91 Cr in March 2022. The company's total assets have increased to 430.49 Cr in March 2025, up from 85.48 Cr in March 2021, while total liabilities have also surged to 430.49 Cr, reflecting a growing debt position. Cash flow from operating activities has deteriorated, showing a cash outflow of -49.00 Cr in March 2025, compared to a positive cash flow of 13.00 Cr in March 2022. Overall, while Zota Health Care has expanded its revenue base, it faces significant challenges in profitability and cash flow management.

Should I buy, sell or hold Zota Health Care?

Is Zota Health Care technically bullish or bearish?

As of December 1, 2025, Zota Health Care's trend is mildly bullish due to daily moving averages, despite mixed signals from weekly and monthly indicators suggesting some caution.

As of 1 December 2025, the technical trend for Zota Health Care has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are both mildly bearish, suggesting some caution. The monthly MACD remains bullish, which supports the overall positive outlook. The RSI shows a bearish signal on the monthly timeframe, indicating potential weakness. Overall, while there are mixed signals across different timeframes, the daily indicators provide a bullish bias.

Why is Zota Health Care Ltd falling/rising?

As of 26-Jan, Zota Health Care Ltd's stock price is declining to 1,314.20, down 4.49%, due to significant drops in operating profits and high debt levels. Despite some institutional investment, the company's poor financial results and negative profit trends indicate a risky investment environment.

As of 26-Jan, Zota Health Care Ltd's stock price is falling, currently at 1,314.20, which reflects a decrease of 61.8 points or 4.49%. This decline can be attributed to several negative factors impacting the company's financial health. Notably, the company has experienced a significant drop in operating profits, with a compound annual growth rate (CAGR) of -310.58% over the last five years. This indicates a severe inability to generate sustainable profits, which is further highlighted by a high Debt to EBITDA ratio of 9.09 times, suggesting challenges in servicing its debt.<BR><BR>Additionally, the company reported disappointing financial results for the quarter ending September 25, with a profit before tax (PBT) of -16.02 crore, marking a decline of 21.09%, and a profit after tax (PAT) of -15.95 crore, down 31.8%. The low debtors turnover ratio of 0.69 times further emphasizes the company's struggles in managing its receivables effectively.<BR><BR>While there has been an increase in institutional investor participation, with a 5.65% rise in their stake, the overall weak long-term fundamental strength and the negative operating profits create a risky investment environment. Despite a strong performance over the past year, with a return of 37.10%, the substantial drop in profits by 78.3% raises concerns among investors, contributing to the stock's current downward trend.

Which are the latest news on Zota Health Care?